Tiger Brokers

  • Quotes
  • Invest
  • Pricing
  • Download
  • Rewards
  • Help
  • TigerAI
  • Institution
    • Wealth and asset manager
    • Proprietary trading institutions
    • Introducing brokers
    • Third-party service provider
    • Esop
  • About
    • About us
    • Newsroom
    • Awards
  • LOGIN
  • SIGN UP
US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Citius Pharmaceuticals, Inc.

0.6250
+0.04968.62%
Volume:1.46M
Turnover:933.55K
Market Cap:17.16M
PE:-0.29
High:0.6700
Open:0.5777
Low:0.5777
Close:0.5754
52wk High:2.19
52wk Low:0.4687
Shares:27.45M
Float Shares:26.96M
Volume Ratio:4.38
T/O Rate:5.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1219
EPS(LYR):-3.3830
ROE:-81.09%
ROA:-26.57%
PB:0.26
PE(LYR):-0.18

Loading ...

OverviewCompanyNewsFilings

Citius Oncology to Attend USCLC Annual Workshop to Discuss LYMPHIR™ in CTCL Treatment Sessions

Reuters
·
Mar 24

Citius Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 12

Citius Oncology Inc - No Unexpected Safety Signals or Serious Immune-Related Adverse Events Observed

THOMSON REUTERS
·
Mar 10

Citius Oncology Announces Positive Topline Results From Investigator‑Initiated Phase 1 Study of Lymphir™ in Combination With Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

THOMSON REUTERS
·
Mar 10

Citius Oncology Inc - Phase 1 Study Shows 24% Objective Response Rate, 48% Clinical Benefit Rate

THOMSON REUTERS
·
Mar 10

BUZZ-Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy

Reuters
·
Mar 04

Citius Oncology reports positive Phase 1 topline data for LYMPHIR before CAR-T in high-risk DLBCL

Reuters
·
Mar 04

Citius Pharmaceuticals Secures $3.8 Million in NJEDA NOL Program Funding

Reuters
·
Feb 24

Citius Pharmaceuticals Inc. Announces Annual Stockholders Meeting

Reuters
·
Feb 24

Analyst Rate

Buy
Buy
100.00%
Hold
0.00%
Sell
0.00%

Corporate Actions

Financial Report Announcement
Aug 14, 2026 Post-Mkt
Financial Report Announcement
May 15, 2026
Financial Report Announcement
Feb 13, 2026 Pre-MKt
Financial Report Announcement
Dec 23, 2025 Post-Mkt
Financial Report Announcement
Aug 12, 2025 Post-Mkt

Dividend History

no data

No relevant data is available

Valuation Analysis

-0.29
Current
-3.99
Sector Average
89.50%
Historical Percentile
P/E[TTM]
+1 STD
Average
-1 STD
Current
-0.29
Maximum
-0.17
+1 STD
-0.37
Minimum
-14.39
-1 STD
-7.62
Average
-3.99

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10
     
     
     
     
Company Name:
Tiger Trade Technology Pte. Ltd.
Email Address:
dpo@itiger.com
User Agreement|Privacy Policy

Copyright © Tiger Trade Technology Pte. Ltd.

Product offerings in different jurisdictions may vary.

Information contained on this website is general in nature and does not take into account of your investment objectives, financial situation and specific needs. It should not be regarded as an offer to sell, asolicitation to buy, a recommendation or endorsement for any financial product, nor does it constitute an investment forecast, investment return commitments, investment suggestions or other practical operating opinions. Information contained on this website is for reference only and past performance should not be construed as future performance. Investment involves risks. Before you make an investment decision, you should carefully judge and screen whether the information contained on this website is appropriate for your needs, goals and circumstances.

We strive but cannot guarantee the accuracy, completeness, reliability and timeliness of all information on this website, and we are not responsible for any losses caused by the use of or reliance on relevant information.

The products and services offered on the website are subject to applicable laws, regulations and relevant agreements. Please carefully read and agree to the agreements before using our products and services.